|
|
Layoffs for Schering-Plough, but One Large Insurer Still Backs Ezetimibe
|
| Link ID |
4508 |
| Title |
Layoffs for Schering-Plough, but One Large Insurer Still Backs Ezetimibe |
| Url |
http://www.medscape.com/viewarticle/572489?src=rss |
| Description |
Schering-Plough Corporation announced that 5500 employees are being laid off, with sales and marketing to be hit first. In other news, the company released more emails between Kastelein and executives, arguing that the primary investigator was not kept out of the loop of important study decisions. Heartwire |
| Category |
Articles > Cardiology |
| Keywords |
|
| Date |
Apr 4, 2008 |
| Contact Name |
|
| Email |
|
Write a Review
Add to My Favorite
Refer it to Friend
Report Broken Link
|
|
Other links at Articles > Cardiology |
| 2. |
FDA Approvals: Avalide and Ixempra
|
|
|
The FDA has approved a new indication for irbesartan/hydrochlorothiazide tablets (Avalide) and ixabepilone injection (Ixempra). Medscape Medical News
|
| 3. |
Some MOMENTUM for Continuous Aortic Flow Therapy in Heart Failure
|
|
|
Chronic heart-failure patients with nonischemic etiology and without kidney dysfunction or severe N-terminal pro-brain-natriuretic peptide expression appear to benefit from the device. The data are hypothesis generating at this point, say investigators, and decisions will need to be made about where to go next with the aortic flow therapy. Heartwire
|
| 5. |
Primary Aldosteronism Rarer Than Was Thought
|
|
|
Primary aldosteronism is not the epidemic it has been considered, say Greek researchers, who report a much lower prevalence of this endocrine disorder than has previously been appreciated. Medscape Medical News
|
|
|
